Labels
Breast Cancers
(147)
Genitourinary Cancers
(73)
Lung Cancers
(73)
Gastrointestinal Cancers
(67)
Gynecological Cancers
(56)
Head and Neck Cancers
(50)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Monday, 24 February 2014
Summary Basis of Decision for Xtandi
Health Canada has issued a Notice of Compliance to Astellas Pharma Canada Inc. for the drug product, Xtandi. ased on Health Canada's review, the benefit/risk profile of Xtandi is favourable for the treatment of patients with metastatic castration-resistant prostate cancer in the setting of medical or surgical castration who have received docetaxel therapy. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment